Nymox Seeks European Approval of Fexapotide Triflutate to Treat BPH Symptoms
News
Nymox Pharmaceutical is seeking British, Dutch, German and Spanish government authorization to market Fexapotide triflutate for the treatment of benign prostatic hyperplasia (BPH) symptoms. “Fexapotide has the real potential to alter the way ... Read more